FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977977580> ?p ?o ?g. }

• W2977977580 endingPage "29" @default.
• W2977977580 startingPage "18" @default.
• W2977977580 abstract "Background: After approval, drug developers often pursue trials aimed at extending the uses of a new drug by combining it with other drugs. Little is known about the risk and benefits associated with such research. Methods: To establish a historic benchmark of risk and benefit, we searched Medline and Embase for clinical trials testing anti-cancer drugs in combination within 5 years of approval by the Food and Drug Administration of 12 anti-cancer “index” drugs first licensed 2005–2007 inclusive. Risk was assessed based on grade 3 or above drug-related adverse events; benefit was assessed based on efficacy outcomes and advancement of combinations into clinical practice guidelines or approval by the Food and Drug Administration. Results: We captured 323 published post-approval trials exploring combinations, including 266 unique combination–indication pairings and enrolling 29,835 patients. The pooled risk ratios for treatment-related grade 3–4 severe adverse events and deaths attributed to the study drugs for trials randomized between a combination arm and a comparator were 1.54 (1.33–1.79) and 1.51 (1.16–1.97), respectively. The pooled hazard ratios for overall survival and progression-free survival were 0.99 (0.92–1.05) and 0.85 (0.79–0.93), respectively. None of the combination–indication pairings launched after initial drug approval received approval by the Food and Drug Administration, and 13 pairings (4.9%) were recommended by the National Comprehensive Cancer Network within 5 years of the first trial within that pairing. The proportion of patients in our sample who participated in trials leading to an approval by the Food and Drug Administration or a National Comprehensive Cancer Network guideline recommendation was 12.7% with 5 years of follow-up, and 22.3% among pairings for which there were 8 years of follow-up. Conclusion: Patients were just as likely to benefit in the treatment arm as the control arm in terms of overall survival, but they were more likely to experience a treatment-related severe adverse event in post-approval trials of combination therapy." @default.
• W2977977580 created "2019-10-10" @default.
• W2977977580 creator A5065754067 @default.
• W2977977580 creator A5075892804 @default.
• W2977977580 creator A5086279697 @default.
• W2977977580 date "2019-10-03" @default.
• W2977977580 modified "2023-09-26" @default.
• W2977977580 title "Benefit, burden, and impact for a cohort of post-approval cancer combination trials" @default.
• W2977977580 cites W1830474205 @default.
• W2977977580 cites W1905906989 @default.
• W2977977580 cites W1942897646 @default.
• W2977977580 cites W1968718845 @default.
• W2977977580 cites W1985721677 @default.
• W2977977580 cites W1997362383 @default.
• W2977977580 cites W1997674110 @default.
• W2977977580 cites W2034574002 @default.
• W2977977580 cites W2052335855 @default.
• W2977977580 cites W2054100499 @default.
• W2977977580 cites W2080700070 @default.
• W2977977580 cites W2088254924 @default.
• W2977977580 cites W2099688828 @default.
• W2977977580 cites W2099819908 @default.
• W2977977580 cites W2105909603 @default.
• W2977977580 cites W2143594415 @default.
• W2977977580 cites W2149233601 @default.
• W2977977580 cites W2149626936 @default.
• W2977977580 cites W2154677115 @default.
• W2977977580 cites W2162590828 @default.
• W2977977580 cites W2171154436 @default.
• W2977977580 cites W2277709221 @default.
• W2977977580 cites W2302088846 @default.
• W2977977580 cites W2591900530 @default.
• W2977977580 cites W2600452401 @default.
• W2977977580 cites W2619666607 @default.
• W2977977580 cites W2748476586 @default.
• W2977977580 cites W2751323287 @default.
• W2977977580 cites W2788828598 @default.
• W2977977580 cites W2794397044 @default.
• W2977977580 doi "https://doi.org/10.1177/1740774519873883" @default.
• W2977977580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31580145" @default.
• W2977977580 hasPublicationYear "2019" @default.
• W2977977580 type Work @default.
• W2977977580 sameAs 2977977580 @default.
• W2977977580 citedByCount "4" @default.
• W2977977580 countsByYear W29779775802020 @default.
• W2977977580 countsByYear W29779775802021 @default.
• W2977977580 countsByYear W29779775802022 @default.
• W2977977580 countsByYear W29779775802023 @default.
• W2977977580 crossrefType "journal-article" @default.
• W2977977580 hasAuthorship W2977977580A5065754067 @default.
• W2977977580 hasAuthorship W2977977580A5075892804 @default.
• W2977977580 hasAuthorship W2977977580A5086279697 @default.
• W2977977580 hasBestOaLocation W29779775801 @default.
• W2977977580 hasConcept C121608353 @default.
• W2977977580 hasConcept C126322002 @default.
• W2977977580 hasConcept C168563851 @default.
• W2977977580 hasConcept C17744445 @default.
• W2977977580 hasConcept C177713679 @default.
• W2977977580 hasConcept C197934379 @default.
• W2977977580 hasConcept C199539241 @default.
• W2977977580 hasConcept C207103383 @default.
• W2977977580 hasConcept C2779473830 @default.
• W2977977580 hasConcept C2780035454 @default.
• W2977977580 hasConcept C3018890749 @default.
• W2977977580 hasConcept C44249647 @default.
• W2977977580 hasConcept C535046627 @default.
• W2977977580 hasConcept C71924100 @default.
• W2977977580 hasConcept C98274493 @default.
• W2977977580 hasConceptScore W2977977580C121608353 @default.
• W2977977580 hasConceptScore W2977977580C126322002 @default.
• W2977977580 hasConceptScore W2977977580C168563851 @default.
• W2977977580 hasConceptScore W2977977580C17744445 @default.
• W2977977580 hasConceptScore W2977977580C177713679 @default.
• W2977977580 hasConceptScore W2977977580C197934379 @default.
• W2977977580 hasConceptScore W2977977580C199539241 @default.
• W2977977580 hasConceptScore W2977977580C207103383 @default.
• W2977977580 hasConceptScore W2977977580C2779473830 @default.
• W2977977580 hasConceptScore W2977977580C2780035454 @default.
• W2977977580 hasConceptScore W2977977580C3018890749 @default.
• W2977977580 hasConceptScore W2977977580C44249647 @default.
• W2977977580 hasConceptScore W2977977580C535046627 @default.
• W2977977580 hasConceptScore W2977977580C71924100 @default.
• W2977977580 hasConceptScore W2977977580C98274493 @default.
• W2977977580 hasFunder F4320334506 @default.
• W2977977580 hasIssue "1" @default.
• W2977977580 hasLocation W29779775801 @default.
• W2977977580 hasLocation W29779775802 @default.
• W2977977580 hasOpenAccess W2977977580 @default.
• W2977977580 hasPrimaryLocation W29779775801 @default.
• W2977977580 hasRelatedWork W1573843750 @default.
• W2977977580 hasRelatedWork W2025414842 @default.
• W2977977580 hasRelatedWork W2088320058 @default.
• W2977977580 hasRelatedWork W2092246656 @default.
• W2977977580 hasRelatedWork W2113848764 @default.
• W2977977580 hasRelatedWork W2160976181 @default.
• W2977977580 hasRelatedWork W2388075619 @default.
• W2977977580 hasRelatedWork W2508640481 @default.
• W2977977580 hasRelatedWork W4229371909 @default.

• next